强强联合拓新局！科兴制药引进人福普克乙磺酸尼达尼布 共启呼吸领域全球征程

Core Insights - Kexing Pharmaceutical has entered into an overseas commercialization partnership with Renfu Pharmaceutical's subsidiary, Renfu Puke, for the drug Nintedanib soft capsules, enhancing its product portfolio in the respiratory field and showcasing its strong capabilities in international commercialization [1] Group 1: Product Overview - Nintedanib soft capsules are one of only two approved drugs for the treatment of idiopathic pulmonary fibrosis (IPF), recommended by guidelines, with indications also including chronic fibrotic interstitial lung diseases (ILDs) and systemic sclerosis-related ILD [2] - Nintedanib acts as a multi-target tyrosine kinase inhibitor, blocking the activity of VEGFR, PDGFR, and FGFR to inhibit fibroblast proliferation and inflammatory responses, thereby slowing the progression of pulmonary fibrosis [2] Group 2: Market Potential - The global sales of the original drug reached €3.51 billion in 2023, with a projected increase to €3.766 billion in 2024, reflecting a year-on-year growth of 7.3% [3] - The number of global IPF patients increased from 1.4 million in 2015 to 1.7 million in 2022, with a compound annual growth rate of 3.0%, and is expected to reach 1.8 million by 2025, indicating strong market demand for Nintedanib [3] Group 3: International Expansion - The partnership covers markets outside of China, the U.S., Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay, highlighting the potential for significant international growth [4] - Kexing Pharmaceutical has established a comprehensive internationalization capability, including market insights, efficient registration, and targeted marketing, positioning itself as a pioneer in the internationalization of Chinese pharmaceutical companies [4] Group 4: Strategic Collaboration - The collaboration with Renfu Puke is expected to create synergies, leveraging both companies' strengths in research, production, and international commercialization [5] - Renfu Pharmaceutical, established in 1993 and listed in 1997, is a leading pharmaceutical company in Hubei Province and among the top 20 in China, with a strong presence in various therapeutic areas [5]